Skip to main content
SpringerLink
Log in

New Monoclonal Antibodies for Indolent Non-Hodgkin Lymphoma

  • Chapter
  • First Online:
Non-Hodgkin Lymphoma

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1092 Accesses

Abstract

Over the last few years, several new monoclonal antibodies (mAbs) directed against lymphoid cells have been developed and investigated in indolent ­non-Hodgkin lymphoma (NHL). New generations of anti-CD20 mAbs were engineered to have augmented antitumor activity by increasing complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity and increased Fc binding affinity for the low-affinity variants of the FcγRIIIa receptor on immune effector cells. The second-generation mAbs are humanized or fully human to reduce immunogenicity. They include ofatumumab, veltuzumab, and ocrelizumab. The third-generation mAbs, including AME133v, Pro13192, and GA-101, are also humanized, but, in comparison with the second-generation mAbs, they also have an engineered Fc region designed to increase their effector functions. Some other new mAbs are also active in indolent NHL. These treatments include epratuzumab, apolizumab, galiximab, anti-TRAIL receptors mAbs, and anti-CD40 mAbs. Small modular immunopharmaceuticals (SMIP) that retain Fc-mediated effector functions have been also developed and investigated in preclinical studies and clinical trials. The SMIP molecules include TRU-015 (anti-CD20) and TRU-016 (anti-CD37). In ­addition, zanolimumab is a promising new antibody for the treatment of T CD4+ cell malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Keating GM (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, ­low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445–1476

    Article  PubMed  CAS  Google Scholar 

  2. Bhat SA, Czuczman MS (2009) Novel antibodies in the treatment of non-Hodgkin’s ­lymphoma. Neth J Med 67:311–321

    PubMed  CAS  Google Scholar 

  3. Robak T (2008) Novel monoclonal antibodies for the treatment of chronic lymphocytic ­leukemia. Curr Cancer Drug Targets 8:156–171

    Article  PubMed  CAS  Google Scholar 

  4. Robak T, Robak E (2011) New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25:13–25 10.2165/11539590-000000000-00000

    Article  PubMed  CAS  Google Scholar 

  5. Lim SH, Beers SA, French RR et al (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95:135–143

    Article  PubMed  CAS  Google Scholar 

  6. van Meerten T, Hagenbeek A (2010) CD20-targeted therapy: the next generation of antibodies. Semin Hematol 47:199–210

    Article  PubMed  Google Scholar 

  7. Hutas G (2008) Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 9:1206–1215

    PubMed  CAS  Google Scholar 

  8. Kausar F, Mustafa K, Sweis G et al (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 9:889–895

    Article  PubMed  CAS  Google Scholar 

  9. Morschhauser F, Marlton P, Vitolo U et al (2010) Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 21:1870–1876

    Article  PubMed  CAS  Google Scholar 

  10. Goldenberg DM, Rossi EA, Stein R et al (2009) Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 113:1062–1070

    Article  PubMed  CAS  Google Scholar 

  11. Stein R, Qu Z, Chen S et al (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin Cancer Res 10:2868–2878

    Article  PubMed  CAS  Google Scholar 

  12. Goldenberg DM, Morschhauser F, Wegener WA (2010) Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 51:747–755

    Article  PubMed  CAS  Google Scholar 

  13. Negrea OG, Allen SL, Rai KR et al (2009) Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malignancies [abstract]. Blood 114:3757

    Article  Google Scholar 

  14. Morschhauser F, Leonard JP, Fayad L et al (2009) Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol 27:3346–3353

    Article  PubMed  CAS  Google Scholar 

  15. Hagenbeek A, Gadeberg O, Johnson P et al (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood 111:5486–5495

    Article  PubMed  CAS  Google Scholar 

  16. Robak T (2008) Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther 10:294–309

    PubMed  CAS  Google Scholar 

  17. Teeling JL, Mackus WJ, Wiegman LJ et al (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362–371

    PubMed  CAS  Google Scholar 

  18. Hagenbeek A, Fayad L, Delwail V et al (2009) Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular ­lymphoma [abstract]. Blood 114:935

    Google Scholar 

  19. Robak T (2009) GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 10:588–596

    PubMed  CAS  Google Scholar 

  20. Mössner E, Brünker P, Moser S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393–4402

    Article  PubMed  Google Scholar 

  21. Salles GA, Morschhauser F, Cartron G et al (2008) A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease [abstract]. Blood 93:234

    Google Scholar 

  22. Salles G, Morschhauser F, Lamy T et al (2009) Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin lymphoma (NHL) [abstract]. Blood 114:1704

    Article  Google Scholar 

  23. Bowles JA, Wang SY, Link BK et al (2006) CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108:2648–2654

    Article  PubMed  CAS  Google Scholar 

  24. Friedberg JW, Vose JM, Kahl BS et al (2009) A phase I study of PRO131921, a novel ­anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics [abstract]. Blood 114:3742, ASH Annual Meeting Abstracts

    Article  Google Scholar 

  25. Robak T, Robak P, Smolewski P (2009) TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs 10:1383–1390

    PubMed  CAS  Google Scholar 

  26. Hayden-Ledbetter MS, Cerveny CG, Espling E et al (2009) CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 15:2739–2746

    Article  PubMed  CAS  Google Scholar 

  27. Barone D, Burge DJ, Baum P et al (2005) Prolonged depletion of circulating B cells in ­cynomolgus monkeys after a single dose of TRU-015, a novel CD20 directed therapeutic. Ann Rheum Dis 64(suppl 3):159–160

    Google Scholar 

  28. Barone D (2005) TRU-015, a novel CD20-directed biologic therapy, demonstrates significant ­anti-tumor activity in human tumor xenograft models [abstract]. Proc Am Soc Clin Oncol 24:2549

    Google Scholar 

  29. Carnahan J, Stein R, Qu Z et al (2007) Epratunuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44:1331–1341

    Article  PubMed  CAS  Google Scholar 

  30. Leonard JP, Coleman M, Ketas JC et al (2003) Phase I/II trial of epratuzumab humanized ­anti-CD22 antibody in indolent non-Hodgkin’s lymphoma. J Clin Oncol 21:3051–3059

    Article  PubMed  CAS  Google Scholar 

  31. Leonard JP, Coleman M, Ketas JC et al (2005) Combination antibody therapy with ­epratuzumab and rituximab in relapse or refractory non-Hodgkin’s lymphoma. J Clin Oncol 23:5044–5051

    Article  PubMed  CAS  Google Scholar 

  32. Strauss SJ, Morschhauser F, Rech J et al (2006) Multicenter phase II trial of immunotherapy with the humanized anti CD-22 antibody epratuzumab in combination with rituximab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 24:3880–3886

    Article  PubMed  CAS  Google Scholar 

  33. Wong BY, Dang NH (2010) Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 10:1251–1258

    Article  PubMed  CAS  Google Scholar 

  34. DiJoseph JF, Dougher MM, Kalyandrug LB et al (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res 12:242–249

    Article  PubMed  CAS  Google Scholar 

  35. Advani A, Coiffier B, Czuczman MS et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol 28:2085–2093

    Article  PubMed  CAS  Google Scholar 

  36. Kreitman RJ, Wilson WH, Bergeron K et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241–247

    Article  PubMed  CAS  Google Scholar 

  37. Kreitman RJ, Tallman MS, Coutre S et al (2009) Phase I dose-escalation study of CAT-8015 (HA22), a CD22-specific targeted immunotoxin, in relapsed or refractory hairy cell leukemia. Blood 114:888, ASH Annual Meeting Abstracts

    Google Scholar 

  38. Mone AP, Huang P, Pelicano H et al (2004) HU1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 103:1846–1854

    Article  PubMed  CAS  Google Scholar 

  39. Hill ML, Weiner GJ, Link BK (2005) In vitro activity of the humanized anti-HLA-DR anti­bodies KRN848 and apolizumab in non-Hodgkin’s lymphoma cell lines. Blood 106(Suppl 1):Abstract 4826

    Google Scholar 

  40. Rech J, Repp R, Rech D et al (2006) A humanized HLA-DR antibody (Hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin’s lymphoma: a pilot study. Leuk Lymphoma 47:2147–2154

    Article  PubMed  CAS  Google Scholar 

  41. Stein R, Mattes MJ, Cardillo TM et al (2007) CD74: a new candidate target for the ­immunotherapy of B-cell neoplasms. Clin Cancer Res 13(18 Pt 2):5556s–5563s

    Article  PubMed  CAS  Google Scholar 

  42. Mark T, Martin P, Leonard JP, Niesvizky R et al (2009) Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 18:99–104

    Article  PubMed  CAS  Google Scholar 

  43. Sapra P, Stein R, Pickett J et al (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 11:5257–5264

    Article  PubMed  CAS  Google Scholar 

  44. Chang CH, Sapra P et al (2005) Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 106:4308–4314

    Article  PubMed  CAS  Google Scholar 

  45. Horton HM, Bernett MJ, Peipp M et al (2010) Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116:3004–3012

    Article  PubMed  CAS  Google Scholar 

  46. Luqman M, Klabunde S, Lin K et al (2008) The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 112:711–720

    Article  PubMed  CAS  Google Scholar 

  47. Law CL, Gordon KA, Collier J et al (2005) Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 65:8331–8339

    Article  PubMed  CAS  Google Scholar 

  48. Advani R, Forero-Torres A, Furman RR et al (2009) Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 27:4371–4377

    Article  PubMed  CAS  Google Scholar 

  49. Suvas S, Singh V, Sahdev S et al (2002) Distinct role of CD80 and CD86 in the regulation of the activation of B-cell and B-cell lymphoma. J Biol Chem 277:7766–7775

    Article  PubMed  CAS  Google Scholar 

  50. Bhat S, Czuczman MS (2010) Galiximab: a review. Expert Opin Biol Ther 10:451–458

    Article  PubMed  CAS  Google Scholar 

  51. Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ (2008) The use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 8:277–282

    Article  PubMed  CAS  Google Scholar 

  52. Hariharan K, Anderson D, Leigh B et al (2001) Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan) in B cell lymphoma. Blood 98(Suppl 1):Abstract 2549

    Google Scholar 

  53. Czuczman MS, Thall A, Witzig TE et al (2005) Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 23:4390–4398

    Article  PubMed  CAS  Google Scholar 

  54. Leonard J, Friedberg J, Younes A et al (2007) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory follicular ­lymphoma. Ann Oncol 18:1216–1223

    Article  PubMed  CAS  Google Scholar 

  55. Furman RR, Andritos L, Flinn IW et al (2010) Phase 1 dose escalation study of TRU-016, an ­anti-CD37 SMIPTM protein in relapsed and refractory CLL [Abstract 56]. Blood 116(Suppl):31

    Google Scholar 

  56. Zenz T, Volden M, Mast T et al (2010) Exceptional in vitro activity of CD37 antibodies in CLL [Abstract 2460]. Blood 116:1021

    Article  Google Scholar 

  57. Fearon DT, Carroll MC (2000) Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 18:393–422

    Article  PubMed  CAS  Google Scholar 

  58. Gerber HP, Kung-Sutherland M, Stone I et al (2009) Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 113:4352–4361

    Article  PubMed  CAS  Google Scholar 

  59. Bargou R, Leo E, Zugmaier G et al (2008) Tumor regression in cancer patients by very low doses of T cell engaging antibody. Science 321:974–977

    Article  PubMed  CAS  Google Scholar 

  60. Nagorsen D, Bargou R, Ruttinger D et al (2009) Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 50:886–891

    Article  PubMed  CAS  Google Scholar 

  61. Viardot A, Goebeer M, Sheele JS et al (2010) Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 μg/m2/d is tolerable and highly effective [Abstract 2880]. Blood 116:1186

    Article  Google Scholar 

  62. Horton HM, Bernett MJ, Pong E et al (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 68:8049–8057

    Article  PubMed  CAS  Google Scholar 

  63. Awan FT, Lapalombella R, Trotta R et al (2010) CD19 targeting of chronic lymphocytic ­leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115:1204–1213

    Article  PubMed  CAS  Google Scholar 

  64. Zalevsky J, Leung IW, Karki S et al (2009) The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman ­primates. Blood 113:3735–3743

    Article  PubMed  CAS  Google Scholar 

  65. Humphreys RC, Halpern W (2008) TRAIL receptors: targets for cancer therapy. Adv Exp Med Biol 615:127–158

    Article  PubMed  CAS  Google Scholar 

  66. Pukac L, Kanakaraj P, Humphreys R et al (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430–1441

    Article  PubMed  CAS  Google Scholar 

  67. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS (2007) Augmented ­antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13:4556–4564

    Article  PubMed  CAS  Google Scholar 

  68. Younes A, Vose JM, Zelenetz AD et al (2010) A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s lymphoma. Br J Cancer 103:1783–1787

    Article  PubMed  CAS  Google Scholar 

  69. Wakelee HA, Patnaik A, Sikic BI et al (2010) Phase I and pharmacokinetic study of ­lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 21(2):376–381

    Article  PubMed  CAS  Google Scholar 

  70. Kaplan-Lefko PJ, Graves JD, Zoog SJ et al (2010) Conatumumab, a fully human agonist ­antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 9:618–631

    Article  PubMed  CAS  Google Scholar 

  71. Herbst RS, Kurzrock R, Hong DS et al (2010) A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16:5883–5891

    Article  PubMed  CAS  Google Scholar 

  72. Younes A, Kirschbaum M, Sokol L et al (2009) Safety and tolerability of conatumumab in combination with bortezomib or vorinostat in patients with relapsed or refractory lymphoma. Blood 114:1708

    Google Scholar 

  73. Branco L, Barren P, Mao SY et al (1999) Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 68:1588–1596

    Article  PubMed  CAS  Google Scholar 

  74. Zhang Z, Zhang M, Ravetch JV et al (2003) Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102:284–288

    Article  PubMed  CAS  Google Scholar 

  75. O’Mahony D, Morris JC, Stetler-Stevenson M et al (2009) EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res 15:2514–2522

    Article  PubMed  Google Scholar 

  76. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG et al (2008) Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 3:1157–1171

    Article  PubMed  CAS  Google Scholar 

  77. Kim YH, Duvic M, Obitz E, Gniadecki R et al (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109:4655–4662

    Article  PubMed  CAS  Google Scholar 

  78. Mestel DS, Beyer M, Möbs M et al (2008) Zanolimumab, a human monoclonal antibody ­targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opin Biol Ther 8:1929–1939

    Article  PubMed  Google Scholar 

  79. d’Amore F, Radford J, Relander T et al (2010) Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 150:565–573

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Lodz, Poland

    Tadeusz Robak

Authors
  1. Tadeusz Robak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadeusz Robak .

Editor information

Editors and Affiliations

  1. Div. Hematology & Oncology, Rhode Island Hospital, Eddy St. 593, Providence, 02903, Rhode Island, USA

    Peter J. Quesenberry

  2. , Division of Hematology and Oncology, The Miriam Hospital, Summit Ave 164, Providence, 02906, Rhode Island, USA

    Jorge J. Castillo

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Robak, T. (2013). New Monoclonal Antibodies for Indolent Non-Hodgkin Lymphoma. In: Quesenberry, P., Castillo, J. (eds) Non-Hodgkin Lymphoma. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5851-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5851-7_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5850-0

  • Online ISBN: 978-1-4614-5851-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation